This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $676,584 in funding to The University of Texas MD Anderson Cancer Center to study the co-evolution of cancer subclones and their tumor microenvironment in metastatic triple-negative breast cancer (MTNBC). The project aims to overcome technical and logistical barriers to investigating the genomic and transcriptomic heterogeneity of MTNBC across primary and metastatic sites. Key objectives include reconstructing clonal lineages, mapping phenotypic programs to genetic lineages during metastasis, and analyzing gene expression programs in the stromal and immune tumor microenvironment across organ sites. The goal is to uncover the genomic and transcriptomic underpinnings of metastatic spread in MTNBC that could lead to new therapeutic interventions. The project period runs from April 1, 2025 to March 31, 2030.
Generated 3/25/25, 5:36 AM